|Legal Status:||℞ - Trial|
|Administered By:||Pill - Oral|
|Tumor Target:||Solid Tumors; Schwannoma, Meningioma|
|Inhibits:||anaplastic lymphoma kinase (ALK) and
epidermal growth factor receptor (EGFR) inhibitor
Brigatinib (Alunbrig™) is a clinical trial tumor drug treatment listed for solid tumors. Early mouse trial studies suggest brigatinib may have good results with the reduction of size in solid tumors including; schwannoma and meningioma.
During the mouse trials no growth was seen with long treatment breaks, followed by continued size reduction when the treatment continued again later. If this holds for human trials, breaks for healing from possible side effects or for treatments of other health issues.
This solid tumor trial is available to individuals with neurofibromatosis type 2 (NF2), or other solid tumors.
In mouse trials with brigatinib tumors reduced in size and remained stable during three (3) month breaks in treatment.
No known side effects at this time except possible kidney or liver failure, like all tumor drug treatments.